China's rapid growth exposes limits of South Korea's clinical-trial strengths
"Strengthen collaboration to create a second Leclaza"

South Korea must move beyond a growth strategy centered on conducting clinical trials and transition to a model that directly leads the development of innovative new drugs if it is to gain the upper hand in the global race to develop new cancer treatments, experts say. The rapid growth of Chinese biotech companies means South Korea can no longer maintain its competitiveness solely through its strengths in quickly recruiting patients and efficiently conducting clinical trials.


Cho Byungchul, a professor of medical oncology at Yonsei University College of Medicine, said in a keynote address at the 2026 KONECT International Conference on Clinical Trials, held at LOTTE HOTEL SEOUL in Jung-gu, Seoul, on Oct. 13: "South Korea's next source of competitiveness should come not simply from conducting clinical trials efficiently, but from directly leading the scientific direction and strategy of new drug development."


Cho Byungchul, a professor of medical oncology at Yonsei University College of Medicine, delivers a keynote address at the 2026 Connect International Clinical Trials Conference, held at The Grand Lotte Seoul in Jung-gu, Seoul, on the 13th. Photo by Lee Seongmin

Cho Byungchul, a professor of medical oncology at Yonsei University College of Medicine, delivers a keynote address at the 2026 Connect International Clinical Trials Conference, held at The Grand Lotte Seoul in Jung-gu, Seoul, on the 13th. Photo by Lee Seongmin

View original image

Professor Cho is a physician-scientist who has led the development of innovative cancer treatments by connecting basic and translational research with clinical research. He participated as a key researcher from the early stages of developing Yuhan Corporation's treatment for non-small cell lung cancer, Leclaza (ingredient: lazertinib), and led global clinical trials.


He said that over the past 10 years, South Korea has evolved from a "fast follower" rapidly catching up with advanced countries in oncology clinical research into a global clinical research hub. He explained that world-class medical infrastructure and an efficient clinical trial network have made it possible to recruit patients quickly and obtain high-quality clinical data.


However, he said the competitive landscape has changed as China has made large-scale investments in biotechnology and innovative drug development. "Competition with global pharmaceutical companies, particularly Chinese biotech firms, is growing increasingly fierce," Professor Cho said. "The important question is not whether South Korea has strengths, but whether it is making full use of them."


Professor Cho stressed that to respond to these changes, South Korea must go beyond conducting clinical trials and take the lead from the stage of formulating development strategies. This means actively leveraging the identification of new therapeutic targets, biomarker-based precision medicine, translational research and artificial intelligence (AI), and determining appropriate patient populations, dosages and combination therapies from the clinical trial design stage.


Cho Byoung-chul, a professor of medical oncology at Yonsei University College of Medicine, delivers a keynote address at the 2026 KoNECT International Conference on Clinical Trials, held at The Grand Lotte Seoul in Jung-gu, Seoul, on the 13th. Photo by Lee Sung-min

Cho Byoung-chul, a professor of medical oncology at Yonsei University College of Medicine, delivers a keynote address at the 2026 KoNECT International Conference on Clinical Trials, held at The Grand Lotte Seoul in Jung-gu, Seoul, on the 13th. Photo by Lee Sung-min

View original image

Professor Cho cited Leclaza as a leading success story that brought together South Korea's new drug development capabilities. Leclaza is a lung cancer treatment developed by Yuhan Corporation after it acquired a drug candidate discovered by the Korean biotech venture Genosco. Following Yuhan Corporation's licensing deal with Johnson & Johnson (J&J) in 2018, global clinical development got underway in earnest. In August 2024, the combination therapy with Rybrevant (amivantamab) received U.S. Food and Drug Administration (FDA) approval as a first-line treatment.



"The biotech company provided the drug candidate, universities and hospitals established the scientific and clinical evidence, and the pharmaceutical company contributed its development capabilities and global network," he said.  "We need an ecosystem that connects researchers and supports collaboration from drug discovery through clinical development," he said. He added, "Our goal is not simply to conduct more clinical trials. It is to develop a second Leclaza and build the capabilities to repeatedly achieve that kind of success."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing